Skip to Main Content
TABLE 2

Baseline characteristics and changes after 1 year of treatment in women who did develop diabetes and women who did not during the PIPOD study

Variable*No diabetesDiabetesP value
Baseline      
    n 75  11   
    Age (years) 39.2 ± 6.5  41.2 ± 7.5  0.36 
    BMI (kg/m230.5 ± 4.9  31.0 ± 5.4  0.75 
    Waist-to-hip circumference ratio 0.86 ± 0.07  0.86 ± 0.06  0.90 
    OGTT glucose area (mg · dl−1 · min−1 · 10−318.0 ± 2.7  20.4 ± 2.5  0.01 
    OGTT insulin area (μU · ml−1 · min−111,579 ± 6,939  7,595 ± 2,551  0.08 
    IVGTT insulin area (μU · ml−1 · min−19,954 ± 6,051  7,660 ± 2,249  0.37 
    Si (min · μU−1 · ml−1 · 10−42.32 ± 1.71  2.41 ± 1.31  0.60 
    AIRg (μU · ml−1 · min−1432 ± 296  251 ± 220  0.05 
    DI 866 ± 571  627 ± 646  0.15 
1-year change  P  P  
    n 66  11   
    Weight (kg) 2.1 ± 4.2 0.0001 4.8 ± 3.9 0.002 0.05 
    OGTT glucose area (mg · dl−1 · min−1 · 10−3−1.7 to 3.0 0.0001 −1.2 ± 2.5 0.15 0.57 
    OGTT insulin area (μU · ml−1 · min−1−3,077 to 6,211 0.0002 243 ± 2,970 0.79 0.01 
    IVGTT insulin area (μU · ml−1 · min−1−3,173 to 4,447 0.0001 1,493 ± 5,214 0.36 0.01 
    Si (min · μU−1 · ml−1 · 10−41.33 ± 2.62 0.0003 0.77 ± 2.73 0.37 0.52 
    AIRg (μU · ml−1 · min−123.0 ± 385 0.66 32.9 ± 447 0.81 0.93 
    DI 511 ± 1,033 0.0003 18 ± 1,057 0.96 0.15 
Variable*No diabetesDiabetesP value
Baseline      
    n 75  11   
    Age (years) 39.2 ± 6.5  41.2 ± 7.5  0.36 
    BMI (kg/m230.5 ± 4.9  31.0 ± 5.4  0.75 
    Waist-to-hip circumference ratio 0.86 ± 0.07  0.86 ± 0.06  0.90 
    OGTT glucose area (mg · dl−1 · min−1 · 10−318.0 ± 2.7  20.4 ± 2.5  0.01 
    OGTT insulin area (μU · ml−1 · min−111,579 ± 6,939  7,595 ± 2,551  0.08 
    IVGTT insulin area (μU · ml−1 · min−19,954 ± 6,051  7,660 ± 2,249  0.37 
    Si (min · μU−1 · ml−1 · 10−42.32 ± 1.71  2.41 ± 1.31  0.60 
    AIRg (μU · ml−1 · min−1432 ± 296  251 ± 220  0.05 
    DI 866 ± 571  627 ± 646  0.15 
1-year change  P  P  
    n 66  11   
    Weight (kg) 2.1 ± 4.2 0.0001 4.8 ± 3.9 0.002 0.05 
    OGTT glucose area (mg · dl−1 · min−1 · 10−3−1.7 to 3.0 0.0001 −1.2 ± 2.5 0.15 0.57 
    OGTT insulin area (μU · ml−1 · min−1−3,077 to 6,211 0.0002 243 ± 2,970 0.79 0.01 
    IVGTT insulin area (μU · ml−1 · min−1−3,173 to 4,447 0.0001 1,493 ± 5,214 0.36 0.01 
    Si (min · μU−1 · ml−1 · 10−41.33 ± 2.62 0.0003 0.77 ± 2.73 0.37 0.52 
    AIRg (μU · ml−1 · min−123.0 ± 385 0.66 32.9 ± 447 0.81 0.93 
    DI 511 ± 1,033 0.0003 18 ± 1,057 0.96 0.15 

Data are means ± SD from women who had baseline tests and returned for at least one follow-up visit. One-year change data are from the subset of 77 women who had both an OGTT and IVGTT after 1 year of pioglitazone treatment and at least one subsequent follow-up visit.

*

Definitions of variables and units appear in Table 1.

By two-group t test.

By paired t test within each group.

Close Modal

or Create an Account

Close Modal
Close Modal